Skip to content
Homepage
Author:
Siren Biotechnology, Inc.
Posted Date:
June 26, 2026
Siren Biotechnology Awarded $8M in Non-Dilutive Grant Funding from the California Institute for Regenerative Medicine (CIRM) to Support Clinical Development of SRN-101 in High-Grade Glioma
Siren Biotechnology, Inc.
June 26, 2026
Siren Biotechnology Publishes Foundational AAV Immuno-Gene Therapy Data and Announces Presentations at ASGCT 2026
Siren Biotechnology, Inc.
April 27, 2026
Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Glioma
Siren Biotechnology, Inc.
March 23, 2026
Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma
Siren Biotechnology, Inc.
February 24, 2026
Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage
Siren Biotechnology, Inc.
January 28, 2026
